3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
2
Gastrointestinal
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Pulmonary Embolism
1
Gastrointestinal Neoplasms
1
Interventions
Oxaliplatin
300
Fluorouracil
272
Bevacizumab
237
Gemcitabine
236
Leucovorin
212
Capecitabine
207
pembrolizumab
201
Nivolumab
158
Irinotecan
158
Cisplatin
150
Specimen Handling
144
Magnetic Resonance Spectroscopy
130
130-nm albumin-bound paclitaxel
118
Paclitaxel
109
durvalumab
107
Cetuximab
104
Radiotherapy
99
atezolizumab
94
Drug Therapy
94
Biopsy
93
tislelizumab
81
Albumin-Bound Paclitaxel
81
Taxes
74
Folfox protocol
68
lenvatinib
67
Carboplatin
66
regorafenib
60
Blood Specimen Collection
60
sintilimab
54
Ipilimumab
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
abelacimab
×
Gastrointestinal
×
1 year
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled